MET — MetLife, Inc.

Sentiment turned decisively positive after the 2026-08-05 Q2 print: adjusted earnings of $1.6B / $2.43 per share beat the ~$2.30-2.37 consensus and rose ~20% YoY, total premiums, fees and other revenues grew 7% to $13.7B, and management simultaneously announced a new $3B share repurchase authorization (over $1.1B returned in the quarter alone). Sell-side reacted fast - Morgan Stanley lifted its target to $111, Wells Fargo to $109, JPMorgan to $108 - leaving a consensus 'Moderate Buy/Outperform' and an average 12-month target of roughly $101-107 with a high of $119. The tape confirms it: as of 2026-09-13 the stock sat 17.9% above its 200-day moving average and up 9.3% over three months, with RSI at a healthy-but-not-stretched 54.4. The KBW Insurance Conference in September 2026 added to it, with management saying the multi-year 'New Frontier' capital-light strategy is running ahead of schedule.

The GAAP quarterly series is noisy enough that you have to read two stories at once. Reported revenue went $15.87B (Q3'23) -> $19.03B (Q4'23) -> $15.90B (Q1'24) -> $17.49B (Q2'24) -> $18.30B (Q3'24) -> $18.44B (Q4'24) -> $18.26B (Q1'25) -> $17.18B (Q2'25) -> $16.88B (Q3'25) -> $23.81B (Q4'25) -> $19.07B (Q1'26) -> $18.88B (Q2'26). Year-over-year that reads -1.8%, -7.7%, +29.1%, +4.4%, +9.9% over the last five prints - i.e. a genuine return to positive YoY revenue growth in the last two quarters after a soft 2025. The Q4 2025 spike (+29% YoY, with gross profit of $7.27B versus $2.94B in Q3'25) is a market/derivative-driven outlier, not organic growth, and the deterministic score's note about the +41% sequential jump is a real distortion to be aware of. GAAP operating margin has been sliding, from 10.9% in Q3'24 to 7.2% (Q3'25), 4.7% (Q4'25), 7.9% (Q1'26) and 5.5% (Q2'26), and GAAP diluted EPS went $1.81 (Q3'24) -> $1.78 (Q4'24) -> $1.28 (Q1'25) -> $1.03 (Q2'25) -> $1.22 (Q3'25) -> $1.17 (Q4'25) -> $1.74 (Q1'26) -> $1.08 (Q2'26). That looks like deceleration - and it is exactly why the mechanical score reads 'Fair' - but it is mostly net investment and derivative mark noise. Management's adjusted numbers show the opposite: Q2 2026 adjusted EPS of $2.43, +20% YoY, on 7% PFO growth and a 17.0% adjusted ROE. Cash generation supports the adjusted view: trailing four-quarter operating cash flow through Q2 2026 was ~$16.57B versus ~$15.75B a year earlier (+5.2%), and the accruals ratio is -0.2% (cash flow running slightly ahead of reported income - the healthy, conservative pattern). Net: the underlying business is stable-to-accelerating, the reported series is not. Treat 2025's GAAP weakness and 2026's GAAP rebound as noise around a mid-single-digit-to-low-double-digit adjusted earnings trend.

As of 2026-09-13, MET at $97.14 looked fair-to-attractive on earnings and expensive on book - the two metrics disagree, and which one you believe matters. On GAAP trailing numbers it is not cheap: 18.5x trailing EPS of $5.561 versus a 5-year average P/E of 17.2x, and a PEG of -1.593 that is meaningless because the trailing growth base is distorted. But the trailing GAAP P/E is the wrong lens here. On the $10.027 consensus forward EPS the forward P/E is only ~9.7x - a large discount to the 5-year average and to the ~11-12x a large-cap life insurer with a 17% adjusted ROE and a genuine capital-light mix shift can command (peers like AFL run around 10x). P/S of 0.795 is essentially in line with the 5-year average of 0.78. The offset is book value: at $27.32B of stockholders' equity and ~643M shares, book is ~$42.46/share and P/B is 2.32x - a rich multiple for a life insurer, though GAAP book is depressed by AOCI/derivative marks, so the headline P/B overstates the true premium. The 2.41% dividend yield is unremarkable but well covered. Verdict: fairly valued with a modest value tilt on forward earnings, not a bargain on asset value.

The single most important thing to watch with MET is the gap between 18.5x trailing GAAP earnings and ~9.7x forward earnings. That spread exists because GAAP EPS ($5.561 TTM) is being dragged down by derivative and net-investment swings while adjusted operating EPS is running near a $9.5-10 annualized pace. If adjusted earnings keep compounding at ~10-15% and the derivative/AOCI drags fade, the headline P/E compresses toward the forward multiple without the price needing to move - that is the bull case, and it is why the stock could keep grinding higher even after a 42.9% six-month run. The bear case is that rates/credit move against the portfolio and the GAAP-vs-adjusted gap persists, in which case the stock is really trading at a full ~10x on a business growing high-single-digits with a book value that has quietly shrunk from $30.0B (12/31/23) to $27.3B (6/30/26). Practically: buy the adjusted-earnings story, but verify it each quarter against cash flow (which has been confirming) and against buyback share-count reduction under the new $3B authorization. Do not pay up for a GAAP beat that never arrives.

As of 2026-09-13 the technical picture was constructive but no longer early. RSI(14) stood at 54.4 - dead neutral, neither overbought nor oversold. Price was 1.01% above the 20-day SMA (~$96.2), 2.08% above the 50-day SMA (~$95.2) and 17.92% above the 200-day SMA (~$82.4), which is a textbook uptrend, but the enormous 200-day gap tells you the bulk of the re-rating already happened in the preceding six months (+42.92% six-month return; +9.34% three-month; -0.49% one-week; +0.50% one-month). At $97.14 against a 52-week range of $67.33-$100.93, the stock is consolidating just below its high rather than breaking out. Entry-timing implication: this is not a chase. RSI has room to run, but a pullback toward the 50-day (~$95) or a base-building pause near $96-97 is a materially better risk/reward than buying the top of a 43% move. A decisive close above $100.93 would signal the next leg; a break below the 50-day would suggest the momentum trade is unwinding.

• Interest rates and the curve: elevated rates have lifted net investment income on new general-account fixed-income purchases - the main earnings tailwind - but a Fed easing cycle would compress new-money yields and pressure NII, while rate volatility swings the value of the existing bond portfolio (and hence AOCI and GAAP book value).
• Credit spreads and the credit cycle: MET runs a ~$748B asset base; a widening-spread or commercial-real-estate shock would hit both mark-to-market and credit-loss assumptions in the general account.
• Sector rotation and rate-cut expectations: life insurers are classic value/rate-sensitive vehicles, so positioning swings with the market's view on the Fed path and on financials generally can move MET more than its own fundamentals do (beta 0.759).
• Regulatory capital regimes: state insurance regulation and risk-based capital rules in the U.S. plus local regimes across Asia and Latin America set the amount of capital that must be held and constrain buyback capacity.
• Currency and international demand: meaningful Asia and Latin America exposure means dollar strength/weakness and local market dislocations feed directly into segment results, as management flagged with 'sporadic market-related pressures in Asia' in September 2026.

• Q3 2026 earnings, expected ~2026-11-04 post-market - the key numbers are adjusted EPS versus the ~$2.40+ quarterly run-rate, premiums/fees/other revenue growth, adjusted ROE, the buyback pace under the new $3B authorization, and PRT pipeline conversion after management flagged slower pension risk transfer timing.
• Execution of the $3B share repurchase authorization announced on 2026-08-05 - sustained buying at ~9.7x forward earnings is directly EPS-accretive and is the cleanest lever management controls.
• Continued progress on the 'New Frontier' capital-light mix shift (MetLife Investment Management, group benefits) - management said in September 2026 the plan is running ahead of schedule, and further ROE expansion is the argument for a higher multiple.
• Further sell-side target revisions following the August 2026 upgrades (Morgan Stanley to $111, Wells Fargo to $109, JPMorgan to $108) - the consensus target of ~$101-107 currently sits only modestly above the 2026-09-13 price of $97.14, so upgrades are needed to sustain momentum.
• The Fed path and any change in NII guidance - a faster easing cycle would be the most likely source of a negative estimate revision.

• The GAAP-versus-adjusted earnings disconnect. Q2 2026 GAAP diluted EPS was $1.08 while adjusted EPS was $2.43 - a $1.35/share gap driven by derivative and realized-investment swings. If that gap widens rather than narrows, the headline 18.5x trailing P/E stays high, reported book value keeps eroding, and the 'cheap on forward earnings' case rests entirely on management's definition of adjusted.
• PRT and institutional pension risk transfer timing. Management explicitly flagged slower PRT pacing at the September 2026 KBW conference; a multi-quarter normalization in institutional volumes would hit the retirement segment's growth optics even if it is timing rather than demand.
• Credit and spread risk on a ~$748B balance sheet. A significant credit event, commercial-real-estate deterioration, or a sharp spread widening would flow straight through to net investment income, realized losses, and book value.
• Rate-cut compression of new-money yields, which would slow the net investment income growth that has underpinned the recent earnings beat, plus variable investment income/alternative returns normalizing lower.
• Valuation and book-value erosion. P/B of 2.32x on ~$42.46/share of GAAP book is rich for a life insurer, and stockholders' equity has fallen from $30.0B at 12/31/23 to $27.3B at 6/30/26. The stock has already re-rated 42.9% in six months - most of the multiple expansion may be behind it.
• Asia market dislocations and asset-management integration friction, both called out by management as live near-term headwinds.

MetLife is a solid, reasonably priced compounder - but not a screaming bargain at $97.14 on 2026-09-13. At roughly 9.7x consensus forward EPS of $10.03, with a 2.41% dividend yield, a freshly authorized $3B buyback, a 17.0% adjusted ROE and a genuine mix shift into capital-light fee businesses, the setup supports low-to-mid-teens total returns if execution holds. The problem is that the stock has already run 42.9% in six months, sits 17.9% above its 200-day average, and trades at 2.32x a book value that has actually been shrinking - so the easy re-rating is done and the forward P/E is only 'cheap' if you accept management's adjusted earnings definition over GAAP. The core question is whether the ~$5.56 TTM GAAP EPS converges up toward the ~$10 adjusted pace or whether the derivative/AOCI drag is permanent; cash flow (+5.2% TTM YoY) and a -0.2% accruals ratio say the adjusted view is the more honest one. Practical stance: own it or add on a pullback toward the 50-day (~$95), don't chase it into the 52-week high, and re-underwrite after the November 4 Q3 print.

Two-method blend, both anchored to the FMP figures. (1) Earnings multiple: I applied 10.5x to the $10.027 consensus forward EPS - a modest premium to the ~9x typical of large-cap life peers and justified by the 17.0% adjusted ROE and capital-light mix shift - which yields $105.28, versus the 18.5x trailing GAAP P/E and 5-year average P/E of 17.2x that the distorted GAAP base inflates. (2) Residual-income/book cross-check: a justified P/B of ~2.5x (from an adjusted ROE of ~17% against a ~9% cost of equity and ~4.5% growth) applied to the $42.46 of GAAP book value per share (stockholders' equity of $27.324B divided by ~643M shares implied by the $62.5B market cap at $97.14) yields $106.15. Averaging the two gives $105.7, rounded to $106 - about 9% above the 2026-09-13 price of $97.14 and slightly above the $101.67 recent analyst average target.